Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elicio Therapeutics (ELTX) Cash & Current Investments (2020 - 2026)

Elicio Therapeutics filings provide 4 years of Cash & Current Investments readings, the most recent being $13.6 million for Q4 2023.

  • On a quarterly basis, Cash & Current Investments rose 74.63% to $13.6 million in Q4 2023 year-over-year; TTM through Dec 2023 was $13.6 million, a 74.63% increase, with the full-year FY2023 number at $13.6 million, up 74.63% from a year prior.
  • Cash & Current Investments hit $13.6 million in Q4 2023 for Elicio Therapeutics, down from $16.5 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $130.5 million in Q1 2021 to a low of $598000.0 in Q2 2022.
  • Median Cash & Current Investments over the past 4 years was $21.7 million (2023), compared with a mean of $47.5 million.
  • Biggest five-year swings in Cash & Current Investments: crashed 99.49% in 2022 and later surged 3525.75% in 2023.
  • Elicio Therapeutics' Cash & Current Investments stood at $34.6 million in 2020, then soared by 156.47% to $88.8 million in 2021, then crashed by 91.22% to $7.8 million in 2022, then soared by 74.63% to $13.6 million in 2023.
  • The last three reported values for Cash & Current Investments were $13.6 million (Q4 2023), $16.5 million (Q3 2023), and $21.7 million (Q2 2023) per Business Quant data.